Context: Thyroglobulin (Tg) measurement is a major tool for the follow-up of differentiated thyroid cancer (DTC) patients; however, in patients who do not undergo radioactive iodine (RAI) ablation, normal ultrasensitive Tg levels measured under levothyroxine treatment (usTg/L-T 4 ) are not well defined.
Introduction
The incidence of differentiated thyroid cancer (DTC) in the last 20 years is predominantly due to the increased detection of small papillary thyroid cancers, classified as low-risk DTC (1, 2, 3) . The recurrence rate of these low-risk DTCs is !5% and the benefits of radioactive iodine (RAI) ablation on the survival rate or on the risk of recurrence have not been demonstrated (4, 5, 6) . RAI ablation for low-risk DTC patients is therefore recommended in only selected cases, preferably using a minimal RAI activity and recombinant human thyroid-stimulating hormone (rhTSH) stimulation (7, 8, 9, 10, 11) .
A major argument for RAI administration after surgery is to facilitate follow-up by destroying remnants of normal thyroid tissue, turning serum thyroglobulin (Tg) into a very specific tumor marker. However, it has been shown that the serum Tg level measured on levothyroxine (L-T 4 ) treatment remains a valuable tool for follow-up even in the absence of RAI ablation, with a Tg level below 1 ng/ml in 93-95% of cases (12, 13) . Among 290 patients treated with total thyroidectomy, in the absence of RAI ablation and with a median follow-up of 5 years, 95% of them had a Tg level of !1 ng/ml, measured with a Tg assay with functional sensitivity of 1 ng/ml, and the only patient who relapsed had an increased serum Tg level (13) .
Ultrasensitive Tg (usTg) assays with functional sensitivity of 0.1 ng/ml are now available (14) . Following treatment with total thyroidectomy and RAI ablation, usTg measured under L-T 4 treatment (usTg/L-T 4 ) is able to discriminate patients at risk of recurrence, with different thresholds defined, depending on the study, at 0.15 or 0.27 ng/ml (15, 16) .
Few data on the usefulness of usTg measurement following total thyroidectomy and in the absence of RAI are available. Using an usTg assay with a functional sensitivity of 0.2 ng/ml, Durante et al. (13) showed that 60% of patients had an undetectable (!0.2 ng/ml) Tg level within 12 months after surgery and 79% within 5 years after surgery.
The aim of this single-center retrospective study was to assess usTg/L-T 4 after total thyroidectomy without RAI ablation for low-risk DTC or tumors of uncertain malignant potential (TUMP).
Subjects and methods

Patients
Approval from our institutional review board was obtained for the study. Files of consecutive patients seen in the thyroid clinic between January 2006 and December 2010 with a pathological diagnosis of DTC, TUMP, or both, confirmed by our pathologist (A A G) and who underwent total thyroidectomy with or without neck lymph node dissection and did not receive RAI for ablation were reviewed. Another inclusion criterion was at least one serum Tg measurement on L-T 4 treatment performed at our institution 1-36 months after initial surgery.
Follow-up, usually once annually following surgery, was based on physical examination and usTg/L-T 4 . Neck ultrasonography (US) was performed at 9 months after surgery and then at the discretion of physicians.
Tg measurement
Serum Tg measurement was performed using the chemiluminescent immunoenzymatic «sandwich» assay, Access Thyroglobulin, automated on UniCel DxI 800 instruments (Beckman Coulter, Villepinte, France) with an analytical sensitivity of 0.1 ng/ml. The Tg level was considered as not accurately measured in the presence of Tg antibodies (TgAb) that were quantitatively measured with Access Thyroglobulin Antibody II assay (Beckman Coulter) in routine at each serum Tg determination, with a reference range of 0-4 IU/ml. Serum TSH was measured using the Access HYPERsensitive human TSH (hTSH) assay, a third-generation two-site immunoenzymatic (sandwich) assay automated on Access II Immunoassay System instrument (Beckman Coulter, Fullerton, CA, USA), with a reference range of 0.34-5.60 mIU/l.
Neck US
Neck US was performed with a high-resolution ultrasound system (Aplio ultrasound machine; Toshiba Medical, Puteaux, France) equipped with a high-energy 14 MHz linear probe (PZT; Toshiba), allowing to work in fundamental B-mode (lateral resolution: 0.17 mm; axial resolution: 0.11 mm) and in power Doppler mode (rate of 12 frames/s, limit detection of 5 cm/s with a pulse repetition frequency (PRF) of 17 KHz). US examination included both central and lateral neck compartments. Suspicion of a malignant lymph node was based on the following criteria: hyperechoic punctuations, cystic appearance, peripheral hypervascularization, round-shape node without hyperechoic hilum, and a short axis O7 mm (17) . Neck US was considered abnormal when lymph node metastasis was confirmed with a fine-needle aspiration biopsy (FNAB) for cytology and Tg measurement in the aspirate fluid. Neck US was considered a false positive when FNAB did not show any evidence of malignancy and/or when subsequent neck US was normal. In the other cases, neck US was considered suspicious for malignancy.
Statistical analysis
Quantitative data were expressed in means and S.D. and qualitative data were expressed in percentages.
Results
Patients
The clinical characteristics of the 86 patients (66 females, mean age 50 years, range 15-86 years) who form the basis of this retrospective study are (7), because of a single lymph node metastasis in five cases, a wish of pregnancy in a 40-year-old woman who had pT1N1b DTC and poor clinical condition in an 86-year-old woman who had a pT3Nx DTC.
Serum usTg levels
Postoperative usTg/L-T 4 level was measured in the 76 patients without anti-TgAb at a mean time of 9 months after surgery (range: 1-34 m): it was %0.1 ng/ml in 47 cases (62%), %0.3 in 62 cases (82%), %1 ng/ml in 69 cases (91%), and %2 ng/ml in 73 cases (96%); the concomitant median TSH level was 0.48 mIU/l (mean: 1.56; range: 0.01-15.34 mIU/l). The percentage of patients with a TSH level O2 mIU/l increased with the Tg level, but the association between these categories was not statistically significant ( Table 2 ). In the remaining three patients, usTg/L-T 4 was 3.9, 4.9, and 11 ng/ml with evidence of disease only present in the latter patient (Table 2) . Among the ten patients with detectable postoperative TgAb, the median postoperative TgAb level was 24.1 IU/ml (meanZ67.5, range: 2.6-288.7 IU/ml) and was above the upper limit of the normal range in nine patients.
Neck US and follow-up
During a median follow-up of 2.5 years (range: 0.6-7.2 years), neck US was performed in 72 patients (81%). It was normal in 67 cases including the two patients with a usTg level of 3.9 and 4.9 ng/ml. It was abnormal in the patient with a usTg/L-T 4 level of 11 ng/ml, who had a thyroid cancer recurrence. It was suspicious for malignancy in four cases, but thyroid cancer recurrence was not confirmed in any of these cases with subsequent normal neck US in two cases, lymphoma in one case, and normal benign ectopic thyroid tissue histologically proven in the remaining case. Among the ten patients with detectable serum TgAb, seven were followed up and TgAb became undetectable in three patients, decreased by more than 60% in three, and remained stable in one patient (Fig. 1) .
The patient with persistent disease was a 20-yearold woman with a pT1Nx papillary carcinoma. Her usTg/L-T 4 level measured 7 months after surgery was 11 ng/ml, as described earlier, with metastatic neck lymph nodes in both lateral compartments at neck US. She underwent central and bilateral neck dissection, with six metastatic lymph nodes being removed in both lateral compartments. Following surgery, this patient was considered cured with an usTg level %1 ng/ml and a normal neck US. 
Discussion
Properly selected low-risk DTC patients can be treated with surgery only, without RAI ablation, without decreasing long-term disease-free survival (12, 18) . The follow-up of DTC patients is based on neck US and serum Tg measurement, with an undetectable serum Tg being a criterion of cure. In the absence of RAI ablation, a detectable serum Tg level may be related to persistent disease or normal thyroid remnants (19, 20, 21, 22) . Our study confirms that serum usTg/L-T 4 in the absence of TgAb is a valid tool for the follow-up of patients who did not receive RAI ablation, even in the absence of suppressed TSH levels. In our study, a high usTg/L-T 4 level was observed in the only case of persistent disease that was confirmed by an abnormal neck US and surgery. Moreover, most patients do have a level lower than 2 ng/ml (96%) within the first year following total thyroidectomy. Following RAI ablation, usTg/L-T 4 levels are lower than 0.15 or 0.27 ng/ml (15, 16) in 84% of the patients. We similarly found usTg/L-T 4 level below 0.3 ng/ml in 82% of the patients during the first year of follow-up, which was the threshold (0.27 ng/ml) with the best sensitivity and specificity for defining complete ablation in our previous study (15) . In the rare patients with a higher serum Tg level, the evolution -increasing or decreasing -of serum Tg/L-T 4 during subsequent follow-up is a major tool to interpret Tg/L-T 4 , even in the absence of RAI ablation (13, 23, 24, 25) .
Interestingly, we observed that TgAb spontaneously decreased in most cases, as observed after RAI ablation (26) . Although this needs to be confirmed on a larger series of patients, this suggests that the presence of TgAb may not be an argument for RAI administration.
Our study is, however, limited by its retrospective design, a short follow-up of less than 10 years (27), fewer patients, and the absence of neck US performed in all patients, which may detect small lymph node metastases in the absence of elevated serum Tg (27, 28) . Our results are also dependent on the quality of the surgery performed and can only be applied in patients who underwent total thyroidectomy with a small remnant, and this is the case in our center (29) . It may not apply in patients who underwent less than total thyroidectomy.
In conclusion, for DTC patients well operated by total thyroidectomy and with small thyroid remnants in the absence of RAI ablation, serum usTg measurement is a useful tool for the follow-up. The usTg/L-T 4 is %2 ng/ml in most patients.
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